Dan Iazzetti
Human Resources Officer chez ORIC PHARMACEUTICALS, INC.
Profil
Dan Iazzetti is currently the Vice President & Head-People at Oric Pharmaceuticals, Inc. Previously, he held the position of Senior Vice President-Human Resources at Angion Biomedica Corp.
and Vice President-Human Resources at Five Prime Therapeutics, Inc. He completed his undergraduate degree at Marist College.
Postes actifs de Dan Iazzetti
| Sociétés | Poste | Début |
|---|---|---|
| ORIC PHARMACEUTICALS, INC. | Human Resources Officer | 01/09/2022 |
Anciens postes connus de Dan Iazzetti
| Sociétés | Poste | Fin |
|---|---|---|
| FIVE PRIME THERAPEUTICS, INC. | Human Resources Officer | - |
| ANGN BIOM | Human Resources Officer | - |
Formation de Dan Iazzetti
| Marist College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ORIC PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
Angion Biomedica Corp.
 Angion Biomedica Corp. Pharmaceuticals: MajorHealth Technology Angion Biomedica Corp. operates as a biopharmaceutical company. The firm focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 6, 1998 and is headquartered in Newton, MA. | Health Technology |
